FOLFOX化疗对转移性结直肠癌患者CD4^+CD45RA^+和CD4^+CD45RO^+T细胞的影响及临床意义  

Alteration and clinical significance of CD4^+ CD45RA^+ and CD4^+ CD45RO^+ T cells in metastatic colorectal cancer patients before and after treated with FOLFOX therapy

作　　者：于泽顺[1,2] 耿海涛[2] 石传芹 徐雪[1] 胡涛[1] YU Zeshun GENG Haitao SHI Chuanqin XU Xue HU Tao(Department of Immunology, Binzhou Medical University, Yantai, 264003, P. R. China Department of Oneology,Binzhou Medical University Hospital)

机构地区：[1]滨州医学院免疫学教研室,烟台264003 [2]滨州医学院附属医院肿瘤科

出　　处：《滨州医学院学报》2017年第1期39-41,45,共4页Journal of Binzhou Medical University

摘　　要：目的探讨FOLFOX化疗方案对转移性结直肠癌(mCRC)患者外周血中初始(CD4^+CD45RA^+)和记忆(CD4^+CD45RO^+)T细胞亚群的影响及其临床意义。方法采用CD3、CD4、CD45RO、CD45RA荧光抗体对10例健康对照及27例mCRC患者接受FOLFOX方案化疗前、后的外周血细胞进行标记,流式细胞术检测CD4^+T细胞及其亚群CD4^+CD45RO^+、CD4^+CD45RA^+百分率,并进一步分析其与临床疗效之间的关系。结果与正常对照组相比,mCRC患者化疗前外周血中CD4^+T细胞比例无明显差异(P>0.05);其中CD4^+CD45RA^+T细胞比例明显降低(P<0.01)、CD4^+CD45RO^+T细胞比例明显增高(P<0.05)。与化疗前相比,经FOLFOX化疗后mCRC患者外周血CD4^+T细胞比例明显增高(P<0.001);其中CD4^+CD45RA^+T细胞比例下降(P<0.001)、CD4^+CD45RO^+T细胞的比例明显升高(P<0.05)。分析发现,化疗有效组中,化疗前、后患者CD4^+CD45RA^+比例无明显变化(P>0.05),均高于化疗无效组(P<0.01,P<0.001);化疗后CD4^+CD45RO^+T细胞百分率增高(P<0.05)。结论 FOLFOX化疗可升高mCRC患者外周血中CD4^+T细胞并改变细胞亚群的比例,对CD4^+CD45RA^+比例较高的患者具有较好的疗效。Objective To explore the effect of FOLFOX chemotherapy on the CD4^＋primary T cell（CD4^＋CD45RA^＋）and memory T cell（CD4^＋CD45RO^＋）in metastatic colorectal cancer（mCRC）patient＇s peripheral blood and its clinical significance.Methods After using fluorescence antibody anti-CD3,anti-CD4,anti-CD45 RO and anti-CD45 RA to label peripheral blood cells（PBMC）origin from 10 cases of healthy control and 27 cases of mCRC patients before and after FOLFOX chemotherapy,we detected the percentages of CD4^＋T cells in PBMC and its subsets CD4^＋CD45RO^＋and CD4^＋CD45RA^＋T cells with flow cytometry,and analyzed the difference of these T cell subsets and their relationship with curative effects.Results Compared with healthy people,the ratio of CD4^＋T cell in mCRC patient＇s PBMC before FOLFOX treatment had no difference（P〈0.05）,while the ratio of CD4^＋CD45RA^＋and CD4^＋CD45RO^＋T cell in CD4^＋T cells decreased（P〈0.01）and increased（P〈0.05）,respectively.After FOLFOX therapy,both of the CD4^＋T celsl and CD4^＋CD45RO^＋T percentage was higher than that in prechemotherapy（P〈0.001,P〈0.05）,while CD4^＋CD45RA^＋T cell was just opposite（P〈0.001）.Meanwhile,in the group of mCRC patients who showed effects for FOLFOX chemotherapy,the percentage of CD4^＋CD45RA^＋cells in their CD4^＋T cells before and after chemotherapy was no difference（P〉0.05）,but significantly higher than that in patients ineffective（P〈0.01,P〈0.001）,the percentage of CD4^＋CD45RO^＋T cells was also higher than pre-chemotherapy（P〈0.05）.Conclusion The chemotherapy of FOLFOX regimen not only could increase CD4^＋T cells,change the ratio of T cell subsets such as CD4^＋CD45RA^＋and CD4^＋CD45RO^＋T cells,but also show more effects to cure the mCRC patients with higher ratio of CD4^＋CD45RA^＋.

关 键 词：转移性结直肠癌 FOLFOX化疗 CD4+T细胞 初始T细胞 记忆T细胞 

分 类 号：R735.3[医药卫生—肿瘤]